A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography.
Aged
Asia
/ epidemiology
Biomarkers
/ blood
Computed Tomography Angiography
Coronary Angiography
/ methods
Coronary Artery Disease
/ diagnostic imaging
Coronary Stenosis
/ diagnostic imaging
Coronary Vessels
/ diagnostic imaging
Cross-Sectional Studies
Drug Therapy, Combination
Dyslipidemias
/ blood
Europe
/ epidemiology
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Hypolipidemic Agents
/ therapeutic use
Lipids
/ blood
Male
Middle Aged
North America
/ epidemiology
Plaque, Atherosclerotic
Predictive Value of Tests
Prevalence
Registries
Risk Factors
Coronary computed tomography angiography
Coronary plaque composition
Ezetimibe
Fibrate
Niacin
Non-statin therapy
Journal
Journal of cardiovascular computed tomography
ISSN: 1876-861X
Titre abrégé: J Cardiovasc Comput Tomogr
Pays: United States
ID NLM: 101308347
Informations de publication
Date de publication:
Historique:
received:
03
07
2018
revised:
17
12
2018
accepted:
14
01
2019
pubmed:
13
2
2019
medline:
14
6
2019
entrez:
13
2
2019
Statut:
ppublish
Résumé
Non-statin therapy (NST) is used as second-line treatment when statin monotherapy is inadequate or poorly tolerated. To determine the association of NST with plaque composition, alone or in combination with statins, in patients undergoing coronary computed tomography angiography (coronary CTA). From the multicenter CONFIRM registry, we analyzed individuals who underwent coronary CTA with known lipid-lowering therapy status and without prior coronary artery disease at baseline. We created a propensity score for being on NST, followed by stepwise multivariate linear regression, adjusting for the propensity score as well as risk factors, to determine the association between NST and the number of coronary artery segments with each plaque type (non-calcified (NCP), partially calcified (PCP) or calcified (CP)) and segment stenosis score (SSS). Of the 27,125 subjects in CONFIRM, 4,945 met the inclusion criteria; 371 (7.5%) took NST. At baseline, patients on NST had more prevalent risk factors and were more likely to be on concomitant cardiac medications. After multivariate and propensity score adjustment, NST was not associated with plaque composition: NCP (0.07 increase, 95% CI: -0.05, 0.20; p = 0.26), PCP (0.10 increase, 95% CI: -0.10, 0.31; p = 0.33), CP (0.18 increase, 95% CI: -0.10, 0.46; p = 0.21) or SSS (0.45 increase, 95% CI: -0.02,0.93; p = 0.06). The absence of an effect of NST on plaque type was not modified by statin use (p for interaction > 0.05 for all). In this cross-sectional study, non-statin therapy was not associated with differences in plaque composition as assessed by coronary CTA.
Identifiants
pubmed: 30745132
pii: S1934-5925(18)30257-0
doi: 10.1016/j.jcct.2019.01.015
pii:
doi:
Substances chimiques
Biomarkers
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Hypolipidemic Agents
0
Lipids
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-104Informations de copyright
Copyright © 2019. Published by Elsevier Inc.